BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35058143)

  • 1. Presence of innate lymphoid cells in allogeneic hematopoietic grafts correlates with reduced graft-versus-host disease.
    Kroeze A; van Hoeven V; Verheij MW; Turksma AW; Weterings N; van Gassen S; Zeerleder SS; Blom B; Voermans C; Hazenberg MD
    Cytotherapy; 2022 Mar; 24(3):302-310. PubMed ID: 35058143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Source of hematopoietic progenitor cells determines their capacity to generate innate lymphoid cells ex vivo.
    Omar SZ; van Hoeven V; Haverkate NJE; Van der Meer JMR; Voermans C; Blom B; Hazenberg MD
    Cytotherapy; 2024 Apr; 26(4):334-339. PubMed ID: 38363249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of human ILC3 from allogeneic and autologous CD34
    Van der Meer JMR; Bulder I; Kuijk C; Kleijer M; Verheij MW; Omar SZ; Haverkate NJE; Dolstra H; Blom B; Hazenberg MD; Voermans C
    Cytotherapy; 2024 Feb; 26(2):136-144. PubMed ID: 38149947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.
    Booth G; Yu Y; Harlan RP; Jacoby CE; Tomic KM; Slater SE; Allen BE; Berklich EM; Knight RJ; Dela Cruz J; Fu R; Gandhi A; Cook RJ; Meyers G; Maziarz RT; Newell LF
    Cytotherapy; 2023 Apr; 25(4):423-431. PubMed ID: 36690537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The generation of human innate lymphoid cells is influenced by the source of hematopoietic stem cells and by the use of G-CSF.
    Moretta F; Petronelli F; Lucarelli B; Pitisci A; Bertaina A; Locatelli F; Mingari MC; Moretta L; Montaldo E
    Eur J Immunol; 2016 May; 46(5):1271-8. PubMed ID: 26840535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early myeloid-derived suppressor cells (HLA-DR
    Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
    Chang YJ; Huang XJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
    Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
    Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
    Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
    Pan L; Delmonte J; Jalonen CK; Ferrara JL
    Blood; 1995 Dec; 86(12):4422-9. PubMed ID: 8541530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation.
    MacDonald KP; Rowe V; Filippich C; Thomas R; Clouston AD; Welply JK; Hart DN; Ferrara JL; Hill GR
    Blood; 2003 Mar; 101(5):2033-42. PubMed ID: 12393418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation.
    Zaucha JM; Gooley T; Bensinger WI; Heimfeld S; Chauncey TR; Zaucha R; Martin PJ; Flowers ME; Storek J; Georges G; Storb R; Torok-Storb B
    Blood; 2001 Dec; 98(12):3221-7. PubMed ID: 11719357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia.
    Ji SQ; Chen HR; Wang HX; Yan HM; Pan SP; Xun CQ
    Biol Blood Marrow Transplant; 2002; 8(5):261-7. PubMed ID: 12064363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate lymphoid cells in graft-versus-host disease.
    Konya V; Mjösberg J
    Am J Transplant; 2015 Nov; 15(11):2795-801. PubMed ID: 26228632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate lymphoid cell recovery and occurrence of GvHD after hematopoietic stem cell transplantation.
    Piperoglou C; Larid G; Vallentin B; Balligand L; Crinier A; Banzet N; Farnarier C; Gomez-Massa E; Adalia AC; ; Michel G; Galambrun C; Barlogis V; Vivier E; Vély F
    J Leukoc Biol; 2022 Jan; 111(1):161-172. PubMed ID: 33847423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.
    Bleakley M; Heimfeld S; Loeb KR; Jones LA; Chaney C; Seropian S; Gooley TA; Sommermeyer F; Riddell SR; Shlomchik WD
    J Clin Invest; 2015 Jul; 125(7):2677-89. PubMed ID: 26053664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.